Gil-Solsona R, Nika MC, Bustamante M, Villanueva CM, Foraster M, Cosin-Tomas M, Alygizakis N, Gomez-Roig MD, Llurba-Olive E, Sunyer J, Thomaidis NS, Dadvand P, Gago-Ferrero P. The potential of sewage sludge to predict and evaluate the human chemical exposome. Environ Sci Technol Lett. 2021 Dec 14;8(12):1077-84. doi: 10.1021/acs.estlett.1c00848
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Bonfill X, Rivero E, Moreno C, Rué M. Changes in cancer mortality in Catalonia and Spain (1975-77 and 1987-89). A comparison with other European countries. Eur J Cancer Prev. 1995 Dec;4(6):453-8.